Ace Alfabeto
Research Subjects
Ace Alfabeto has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Michael Wayne Art Chu
Division of Cardiac Surgery, Department of Surgery, Western University, London Health Sciences Centre, ON, Canada
3 shared publications - Wildor Samir Cubas
Division of Cardiac Surgery, Department of Surgery, Western University, London Health Sciences Centre, ON, Canada
2 shared publications - Yasuhiko Kawaguchi
Department of Cardiovascular Surgery, Nagoya Heart Center , Nagoya, Japan
2 shared publications Jill Gelinas
1 shared publication- Joaquín Gundelach1 shared publication
Jonathan Hong
1 shared publication
Latest Publications
- Open Access
- 14 May 2026
- Published by Elsevier in JTCVS Techniques
- Vol. 38
Novel branch vessel anastomotic device to rapid link the left subclavian artery in hybrid arch frozen elephant trunk repair
- 14 May 2026
- Published by Elsevier in JTCVS Techniques
- Vol. 38
Open AccessNovel branch vessel anastomotic device to rapid link the left subclavian artery in hybrid arch frozen elephant trunk repair
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2026 (1)
Are Homografts Superior to Prosthetic Valves in Destructive Aortic Endocarditis? A Systematic Review and Pairwise Meta‐Analysis of Early–Midterm Outcomes
Background: Destructive aortic endocarditis (DAE) requires complex surgery. Homografts are traditional gold standards, but emerging evidence questions their superiority over prosthetic valves. This systematic review and pairwise meta‐analysis compare early–midterm outcomes. Methods: A comprehensive search of PubMed, Embase, Scopus, and Cochrane (1990–2025) identified studies comparing homografts, mechanical, and bioprosthetic valves for DAE. Outcomes included mortality, reoperation, stroke, reinfection, and midterm survival. Pairwise meta‐analysis and Pearson’s correlation were applied. Results: Sixteen studies (9948 patients) were included (homograft n = 1359; mechanical n = 2717; biological n = 5872). The mean age was 53.5 years, and 74.9% were male. No significant differences were observed in 30‐day mortality (homograft vs mechanical: OR 1.31, 95% CI 0.99–1.72; vs biological: OR 1.15, 95% CI 0.73–1.81), midterm survival (RR 1.00, 95% CI 0.92–1.09; RR 1.06, 95% CI 0.88–1.28), or reinfection (homograft vs mechanical: RR 0.99, 95% CI 0.82–1.19; vs biological: RR 0.77, 95% CI 0.44–1.36). Reoperation was significantly higher with homografts versus mechanical (OR 1.58, 95% CI 1.17–2.14) and biological valves (OR 1.45, 95% CI 1.22–1.72), with no heterogeneity ( I 2 = 0%). Stroke risk was comparable across all comparisons, with nonsignificant numerical trends favoring homografts: homograft vs mechanical (OR 0.86, 95% CI 0.37–1.20), homograft vs biological (OR 0.65, 95% CI 0.30–1.41), and mechanical vs biological (OR 0.99, 95% CI 0.80–1.23). Unadjusted pooled proportions suggested higher early mortality with homografts (19.1%) compared to mechanical (16.8%) and biological (15.1%) valves, though these differences were not statistically significant in adjusted pairwise meta‐analyses. Conclusion: Homografts do not demonstrate definitive superiority for DAE. While nonsignificant numerical trends toward lower stroke rates were observed with homografts, no statistically significant benefits were confirmed for mortality, reinfection, or midterm survival. Homografts were associated with significantly higher reoperation rates without a survival advantage. Valve selection requires patient‐tailored balancing of infection control, durability, and procedural risk.
- 1 January 2026
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2026 (1)
Open AccessAre Homografts Superior to Prosthetic Valves in Destructive Aortic Endocarditis? A Systematic Review and Pairwise Meta‐Analysis of Early–Midterm Outcomes
Background: Destructive aortic endocarditis (DAE) requires complex surgery. Homografts are traditional gold standards, but emerging evidence questions their superiority over prosthetic valves. This systematic review and pairwise meta‐analysis compare early–midterm outcomes. Methods: A comprehensive search of PubMed, Embase, Scopus, and Cochrane (1990–2025) identified studies comparing homografts, mechanical, and bioprosthetic valves for DAE. Outcomes included mortality, reoperation, stroke, reinfection, and midterm survival. Pairwise meta‐analysis and Pearson’s correlation were applied. Results: Sixteen studies (9948 patients) were included (homograft n = 1359; mechanical n = 2717; biological n = 5872). The mean age was 53.5 years, and 74.9% were male. No significant differences were observed in 30‐day mortality (homograft vs mechanical: OR 1.31, 95% CI 0.99–1.72; vs biological: OR 1.15, 95% CI 0.73–1.81), midterm survival (RR 1.00, 95% CI 0.92–1.09; RR 1.06, 95% CI 0.88–1.28), or reinfection (homograft vs mechanical: RR 0.99, 95% CI 0.82–1.19; vs biological: RR 0.77, 95% CI 0.44–1.36). Reoperation was significantly higher with homografts versus mechanical (OR 1.58, 95% CI 1.17–2.14) and biological valves (OR 1.45, 95% CI 1.22–1.72), with no heterogeneity ( I 2 = 0%). Stroke risk was comparable across all comparisons, with nonsignificant numerical trends favoring homografts: homograft vs mechanical (OR 0.86, 95% CI 0.37–1.20), homograft vs biological (OR 0.65, 95% CI 0.30–1.41), and mechanical vs biological (OR 0.99, 95% CI 0.80–1.23). Unadjusted pooled proportions suggested higher early mortality with homografts (19.1%) compared to mechanical (16.8%) and biological (15.1%) valves, though these differences were not statistically significant in adjusted pairwise meta‐analyses. Conclusion: Homografts do not demonstrate definitive superiority for DAE. While nonsignificant numerical trends toward lower stroke rates were observed with homografts, no statistically significant benefits were confirmed for mortality, reinfection, or midterm survival. Homografts were associated with significantly higher reoperation rates without a survival advantage. Valve selection requires patient‐tailored balancing of infection control, durability, and procedural risk.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2026 (1)
The Evolution of Minimally Invasive Cardiac Surgery Literature: A 50‐Year North American Bibliometric Review and Future Trends
Objective: This study provides the first bibliometric analysis of minimally invasive cardiac surgery (MICS) in North America, mapping its evolution, collaboration networks, and research trends while forecasting future scientific trajectories through 2050. Methods: We performed a bibliometric analysis of North American MICS literature (1975–2025) using Scopus and PubMed. Data processed using R (bibliometrix and biblioshiny) enabled network mapping, keyword analysis, and predictive modeling. Metrics included publication growth, document types, authorship, collaboration, citations, h‐index, journals, and research topics. Collaboration networks and thematic evolution were visualized. Future MICS output (2030–2050) was forecasted using linear extrapolation with 95% confidence intervals. Results: We analyzed 1433 publications (United States: 76.3%; Canada: 23.7%). Original articles comprised 48.7%, and case reports comprised 28.7%, with an 8.51% annual growth rate. Among 4800 authors, 89.9% were male, averaging 5.65 coauthors per paper and 22.2% international collaborations. First authors were mainly faculty–surgeons (67.5%) and fellows (15.3%). Top topics are mitral valve (41.7%) and CABG (28.7%). Leading journals are Innovations (16.0%), Annals of Thoracic Surgery (12.6%), Journal of Cardiac Surgery (5.7%), and JTCVS (5.0%). Key affiliations are Cleveland Clinic (13.8%) and Western University (12.5%). Collaborations were strongest with Italy (43.5%) and Germany (32.8%). Forecasting models predicted an annual output of 79 publications by 2030, 93 by 2040, and 107 by 2050 (95% CI 58–146). Conclusions: This inaugural bibliometric analysis of North American MICS outlines five decades of growth, projects continued expansion to 2050, and offers a strategic foundation for future research, funding, and collaboration.
- 1 January 2026
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2026 (1)
Open AccessThe Evolution of Minimally Invasive Cardiac Surgery Literature: A 50‐Year North American Bibliometric Review and Future Trends
Objective: This study provides the first bibliometric analysis of minimally invasive cardiac surgery (MICS) in North America, mapping its evolution, collaboration networks, and research trends while forecasting future scientific trajectories through 2050. Methods: We performed a bibliometric analysis of North American MICS literature (1975–2025) using Scopus and PubMed. Data processed using R (bibliometrix and biblioshiny) enabled network mapping, keyword analysis, and predictive modeling. Metrics included publication growth, document types, authorship, collaboration, citations, h‐index, journals, and research topics. Collaboration networks and thematic evolution were visualized. Future MICS output (2030–2050) was forecasted using linear extrapolation with 95% confidence intervals. Results: We analyzed 1433 publications (United States: 76.3%; Canada: 23.7%). Original articles comprised 48.7%, and case reports comprised 28.7%, with an 8.51% annual growth rate. Among 4800 authors, 89.9% were male, averaging 5.65 coauthors per paper and 22.2% international collaborations. First authors were mainly faculty–surgeons (67.5%) and fellows (15.3%). Top topics are mitral valve (41.7%) and CABG (28.7%). Leading journals are Innovations (16.0%), Annals of Thoracic Surgery (12.6%), Journal of Cardiac Surgery (5.7%), and JTCVS (5.0%). Key affiliations are Cleveland Clinic (13.8%) and Western University (12.5%). Collaborations were strongest with Italy (43.5%) and Germany (32.8%). Forecasting models predicted an annual output of 79 publications by 2030, 93 by 2040, and 107 by 2050 (95% CI 58–146). Conclusions: This inaugural bibliometric analysis of North American MICS outlines five decades of growth, projects continued expansion to 2050, and offers a strategic foundation for future research, funding, and collaboration.